All Posts Tagged With: "Beyond Any Multiple"

How much calcium do we need and does excess cause harm? This Vitamin D newsletter is always reviewing the latest information. It is worth reading the research on Calcium.

Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
www.gordonresearch.com  

Excerpt:

Quest Diagnostics and Cardiovascular Disease
This is a periodic newsletter from the Vitamin D Council, a non-profit trying to end the epidemic of vitamin D deficiency. If you want to unsubscribe, go to the end of this newsletter. If you are not subscribed, you can do so on the Vitamin D Council’s website. 
The Annals of Internal Medicine published two important reviews this month. In the first review, Dr. Anastassios Pittas and colleagues from Tufts University reviewed 106 articles and combined the 32 quality studies, a meta-analysis, looking at “cardiometabolic” outcomes such as diabetes, hypertension and cardiovascular disease. Their conclusion: “Lower vitamin D status seems to be associated with increased risk for hypertension and cardiovascular disease, but we do not yet know whether vitamin D supplements will affect clinical outcomes.” Read on.

Pittas AG, et al. Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010 Mar 2;152(5):307-14.
The second Annals of Internal Medicine review, by Dr. Lu Wang and colleagues at Harvard, looked at studies of vitamin D supplementation and found two randomized placebo controlled trials to combine. Dozens of different types of studies have looked at vitamin D and cardiovascular outcomes. The latitude studies are clear, the closer you live to the equator, the less cardiovascular disease. The dietary studies are mixed, because vitamin D is not contained in the diet, at least in significant amounts.  The epidemiological studies are clear.

Wang L, et al. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med. 2010 Mar 2;152(5):315-23.
Dr. Wang concluded, “To date, evidence from prospective observational studies and randomized controlled trials suggests that vitamin D supplementation at moderate to high doses may have beneficial effects on reducing the risk for cardiovascular disease.” 
About the same time that the two above meta-analyses were published, Dr. Brent Muhlestein, director of cardiovascular research at the Intermountain Medical Center Heart Institute in Murray, Utah, presented a paper at this year’s American College of Cardiology’s annual scientific session in Atlanta. 

Please stop patients from using massive doses of calcium now. The patients all have too much calcium in vascular tissue and now we have data showing that giving calcium is increasing heart disease. And, if possible, try to always administer calcium supplementation with EQUAL AMOUNTS of MAGNESIUM, as I have been teaching for over 20 years now.

Also please realize I use calcium in well over 90 % of my patients. It is in BAM, my multiple called Beyond Any Multiple. I usually never use more than 500 mg of calcium a day for my long-term patients, as that is all most will need since that is the amount we need to offset the excess of phosphorus over calcium in the American diet. This amount will help lower the tendency for the body to develop secondary hyperparathyroidism, which is how the body responds to a chronic dietary intake of more phosphorus than calcium.

Results 15 trials were eligible for inclusion, five with patient level data (8151 participants, median follow-up 3.6 years, interquartile range 2.7-4.3 years) and 11 with trial level data (11 921 participants, mean duration 4.0 years). In the five studies contributing patient level data, 143 people allocated to calcium had a myocardial infarction compared with 111 allocated to placebo (hazard ratio 1.31, 95% confidence interval 1.02 to 1.67, P=0.035). Non-significant increases occurred in the incidence of stroke (1.20, 0.96 to 1.50, P=0.11), the composite end point of myocardial infarction, stroke, or sudden death (1.18, 1.00 to 1.39, P=0.057), and death (1.09, 0.96 to 1.23, P=0.18). The meta-analysis of trial level data showed similar results: 296 people had a myocardial infarction (166 allocated to calcium, 130 to placebo), with an increased incidence of myocardial infarction in those allocated to calcium (pooled relative risk 1.27, 95% confidence interval 1.01 to 1.59, P=0.038). 

Conclusions Calcium supplements (without coadministered vitamin D) are associated with an increased risk of myocardial infarction. As calcium supplements are widely used these modest increases in risk of cardiovascular disease might translate into a large burden of disease in the population. A reassessment of the role of calcium supplements in the management of osteoporosis is warranted.

Longevity Plus had effective answers to osteoporosis with their Beyond Bone, H.R.T. Plus and Beyond Any Multiple but the public will prefer the subsidized poisons offered under our health care system, unless you educate them about the dangers from bisphosphonates like Fosamax.

Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
www.gordonresearch.com

Full article: http://www.healthwatchersnews.com/2010/02/bisphosphonates-bone-strengtheners-or-bone-hardeners/

Excerpt:

Bisphosphonates are now the most widely marketed and prescribed patented, FDA-approved anti-osteoporosis drugs. Bisphosphonates mimic, to some extent, the effects of estrogen on bone in that they work by inhibiting bone resorption [the process by which old bone is removed to make room for new bone]. However, like estrogen, these drugs have no ability to build new bone.

Currently FDA-approved bisphosphonates, including Fosamax (alendronate), Actonel (risedronate), Didronel (etidronate), Boniva (ibandronate), and Reclast (Zometa) (zoledronate), are designed to strengthen bone by inhibiting normal osteoclastic bone resorbing activity, which slows the loss of bone mineral density (BMD), allowing the trabecular architecture to stabilize. Notice that this has nothing to do with stabilizing the balance between estrogen and progesterone, restoring calcium levels, or any other natural process.

Like many other patented drugs, bisphosphonates are synthetic analogs of an important natural bone-building chemical, pyrophosphate, which normally helps bind calcium to bone tissue through a process known as mineralization. Unlike pyrophosphate, however, bisphosphonates actually block normal mineralization as well as osteoclastic bone resorption.

Large, placebo-controlled trials generally show that these drugs can indeed increase BMD and reduce the risk of vertebral, hip, and other nonvertebral fractures in women with osteoporosis—at least in the short run. That’s the good news. Merck, the company that markets the leading bisphosphonate, Fosamax (now also sold generically as alendronate), seized upon results like these to turn its drug into a blockbuster worth as much as $3.6 billion per year. Use of Fosamax and other bisphosphonates has been growing at an especially rapid rate since 2002, when the publication of the Women’s Health Initiative (WHI) results scared women away from “estrogen” replacement, which until then had been the leading conventional method for preventing osteoporosis.

Unfortunately, all may not be so rosy after all. Trials lasting up to 10 years are beginning to raise doubts about the long-term safety and efficacy of bisphosphonates. The main problem is that bisphosphonates not only directly—and unnaturally—inhibit osteoclastic bone resorption, they also indirectly inhibit the other side of the bone-building coin, osteoblastic bone formation.

Lead in teeth and bones increases with calcium loss from menopause. Bone lead correlates to hair lead levels. This research showing that with menopause associated calcium loss from bones, we also suffer calcium loss from teeth and that loss gets replaced by lead.

Garry F. Gordon MD,DO,MD(H)
President, Gordon Research Institute
www.gordonresearch.com

Full article: http://www.springerlink.com/content/k28098wg60887655/

Excerpt:

Abstract  The concentration of trace elements has been measured for dental enamel from 86 healthy human teeth using particle-induced X-ray emission (PIXE). The majority of the teeth (n = 70) were collected from dentists in the county of Oxfordshire in the United Kingdom, although a smaller group (n = 16) were collected from Cornwall. The elements K, Ca, Mn, Fe, Co, Ni, Cu, Zn, Sr, Pb, and Hg have been detected and statistically analyzed by grouping according to sex, age, and geographical location. The concentrations of Fe and Cu were found to be lower in the teeth from female donors (P < 5%) and are believed to result from the continued burden of blood loss during menstruation. Strong positive correlations (P < 0.1%) were found between Ca, Co, Ni, and Zn for all groups; these elements were also found to exhibit a negative correlation (P < 1%) with age for teeth from female donors. This is believed to be related to decalcification during the menopause. Pb was found to exhibit a positive correlation (P < 5%) with age for both sexes, and is believed to substitute for Ca in the Ca hydroxy apatite (HAP) within the dental enamel.
Dentistry for the Health Conscious, Inc., the office of Dr. Diane Meyer is pleased to announce that we have secured several of the leading experts in mercury poisoning, diagnosis and treatments for a Mercury Poisoning Symposium Conference.